Vice President, Quality and Product Development, priMED Medical Products
Class of 2004
During his time in the MBiotech Program, Richard Roy had the opportunity to complete two internships, one at NPS Pharmaceuticals and the other at Aventis Pasteur. Through these two internships, Roy developed his knowledge of Good Manufacturing Practices (GMPs) and Quality Systems. At Aventis Pasteur, he worked in a state-of-the-art facility designed for the production of potential cancer vaccines. Upon graduation, Roy stayed on at Aventis Pasteur as a Validation Technologist.
Soon after, Roy was given the exciting opportunity to oversee the construction and facility qualification of a high-containment oncology pharmaceutical production facility in Mississauga, Ontario as a Project Specialist, Engineering. While at Merck KGaA: Genpharm, Richard worked with the Construction, Engineering, Product Development, Production and Quality Assurance departments to ensure all internal and statutory requirements were met. His work helped support the facility passing a strict Health Canada audit which enabled the company to manufacture pharmaceuticals at that site.
After successfully completing this project, Roy was recruited to join an up-and-coming company called Nucryst Pharmaceuticals, located in Fort Saskatchewan, Alberta. Nucryst developed, manufactured and commercialized medical devices based on nanocrystalline silver technology. Roy joined Nucryst as the Quality Systems Manager. His successes included launching several new products, including Acticoat® Flex, as well as successfully hosting numerous third party audits of the company.
Roy currently manages multiple departments as the Vice President, Quality and Product Development of priMED Medical Products Inc., a successful Canada-based medical device company. Roy's expertise has expanded into many different areas including scientific, clinical, engineering, regulatory, and quality systems/quality assurance. As well, Richard is heavily involved in sales and marketing, logistics, production and business planning.
For Roy, the main benefit of the MBiotech Program was the combination of the many aspects of the Program. For example, the advanced sciences, the management of innovation, a better understanding of regulatory requirements and GMPs, etc. The broad scope of knowledge and experience Roy gained working with cross-functional teams while completing the MBiotech Program has significantly contributed to Roy's success in his career as a team player and as a leader within his company.